Great Point Partners’s AnaptysBio ANAB Stock Holding History

Great Point Partners’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-25,000	Closed	-$627K	–	31
2024 Q2	$627K	Sell	25,000 -951,981	-97%	-$22.2M	0.12%	32
2024 Q1	$22M	Hold	976,981	–	–	3.43%	10
2023 Q4	$20.9M	Buy	976,981 +82,648	+9%	+$1.43M	3.57%	12
2023 Q3	$16.1M	Hold	894,333	–	–	2.93%	14
2023 Q2	$18.2M	Buy	894,333 +90,000	+11%	+$1.82M	3.56%	12
2023 Q1	$17.5M	Buy	804,333 +789,333	+5,262%	+$19.2M	3.44%	13
2022 Q4	$465K	Buy	+15,000	New	+$424K	0.09%	42
2022 Q3	–	Sell	-453,118	Closed	-$9.2M	–	42
2022 Q2	$9.2M	Sell	453,118 -246,882	-35%	-$5.47M	2.21%	20
2022 Q1	$17.3M	Buy	700,000 +107,750	+18%	+$3.26M	4.19%	12
2021 Q4	$20.6M	Buy	592,250 +42,705	+8%	+$1.35M	4.57%	5
2021 Q3	$14.9M	Buy	549,545 +149,494	+37%	+$3.79M	3.47%	11
2021 Q2	$10.4M	Buy	+400,051	New	+$9.59M	2.18%	23

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Great Point Partners's ANAB Position: Q3 2024 in Review

Great Point Partners sold out of AnaptysBio (ANAB) in Q3 2024, closing a stake of 25,000 shares — an estimated $627K sold.

Great Point Partners first reported a position in ANAB in Q2 2021 and held it in 12 quarters. The position peaked at $22M in Q1 2024. 160 funds tracked by Wall St. Rank hold ANAB as of Q3 2024.

Great Point Partners reported no remaining AnaptysBio position as of Q3 2024 after selling out during the quarter.
Great Point Partners sold 25,000 AnaptysBio shares in Q3 2024, an estimated $627K.
Great Point Partners first reported a position in AnaptysBio in Q2 2021 and held it in 12 quarters.
Great Point Partners's AnaptysBio position peaked at $22M in Q1 2024.
160 funds tracked by Wall St. Rank held AnaptysBio as of Q3 2024.

Based on Great Point Partners's 13F filing for Q3 2024, filed 13 Nov 2024.